Trademark Overview
On Monday, June 9, 2025, a trademark application was filed for RAXVID with the United States Patent and Trademark Office. The USPTO has given the RAXVID trademark a serial number of 99225404. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, September 18, 2025. This trademark is owned by Pfizer Inc.. The RAXVID trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
